Neurology Xagena
Many patients with Parkinson's disease develop mild cognitive impairment ( MCI ) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis ...
Prostate cancer growth and progression may be linked to neurogenesis and to medical anti- Parkinson treatment, but results are inconclusive. Therefore, researchers have examined the association betwee ...
Multiple sclerosis is an autoimmune inflammatory neurological disease with complex aetiology where the causes are not completely known. The main aim of this thesis was to investigate the influence o ...
Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Researchers have assessed associations between anti-drug antibody ...
New disease-modifying treatment strategies in multiple sclerosis offer possibilities for individualised treatment. In a study, researchers evaluated patient-reported outcome measures before and afte ...
Verubecestat is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 ( BACE1 ) for the potential treatment of Alzheimer’s disease. A resear ...
New efficacy data for investigational Cladribine tablets were presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis ( ECTRIMS ), in London. The fi ...
New results from the REGAIN study, a global, placebo-controlled phase 3 registration trial of Eculizumab ( Soliris ) in patients with refractory generalized myasthenia gravis ( gMG ), were presented a ...
A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin 9 ( PCSK9 ) inhibitors Alirocumab and Evolocumab. Researchers have inve ...
New research from researchers based at The Westmead Institute in Sydney has drawn a link between the genetic and environmental circumstances of multiple sclerosis, which affects 2.1 million people wor ...
Traumatic brain injury with a loss of consciousness may be associated with later development of Parkinson's disease but not Alzheimer's disease or incident dementia, according to a study conducted at ...
The results from the phase 2 SYNERGY study evaluating Opicinumab ( anti-LINGO-1 ), an investigational, fully human monoclonal antibody being developed as a potential neuroreparative therapy in people ...
The pathogenesis of rosacea is unclear, but increased matrix metalloproteinase target tissue activity appears to play an important role. Parkinson disease and other neurodegenerative disorders also di ...
Northwestern Medicine researchers have discovered a new cause of Parkinson's disease, mutations in a gene called TMEM230. This appears to be the third gene definitively linked to confirmed cases of th ...
A promising approach to neurotherapeutics involves activating the nuclear-factor-E2-related factor 2 ( Nrf2 ) / antioxidant response element signaling, which regulates expression of antioxidant, anti- ...
